Skip to main content
. 2022 Feb 24;51:102268. doi: 10.1016/j.redox.2022.102268

Fig. 6.

Fig. 6

Everolimus overcomes dexamethasone resistance in vitro. (A) Specific cell death after 24 h' treatment with everolimus (Eve, 10 μM), dexamethasone (Dex, 1 μM) or both drugs (Eve + Dex) in the presence (+) or absence (−) of NAC (500 μM) measured in Jurkat cells (3 independent experiments, 3 replicates each) and PDX 9, 13, 19, 39 and 46 (3 replicates each); mean values and standard error bars are shown. (B) The combination index of everolimus and dexamethasone in PDX 9, 19, 39 and 46 (black, red, blue and green line, respectively) was calculated using CompuSyn software. The FA (fraction affected) was calculated using specific cell death values measured as percentages of PI-positive cells. It was not possible to calculate the combination index for PDX13, as it was refractory to dexamethasone-induced cell death. (C) Specific cell death after 24 h' treatment with everolimus (Eve, 10 μM), dexamethasone (Dex, 1 μM) or both drugs (Eve + Dex) in primary tumor cells from T-ALL patients (N = 17); mean values and standard error bars are shown. The indicated pairwise comparisons were statistically significant with the Mann-Whitney test; *** indicate p values < 0.001, ** <0.01 and * < 0.05. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)